The safety and pharmacological activity of CGX1321 have inspired a pipeline of novel therapies for various indications that capitalizes the fundamental WNT biology in cancer and tissue repair/regeneration. In addition to the ongoing clinical trials, Curegenix plans to advance at least three additional programs into clinical trials over the next three years for oncology, fibrosis and cartilage regeneration where WNT inhibitors have shown clinical or preclinical activities.